Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex  >  All News

News : Economy & Forex
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies / ForexCryptocurrenciesEconomic EventsPress releases

J&J raises forecast after quarterly profit beats estimates

share with twitter share with LinkedIn share with facebook
07/16/2020 | 06:21am EDT
FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the NYSE in New York

Johnson & Johnson raised its full-year profit forecast and beat analysts' estimates for quarterly earnings on Thursday as strength in its pharmaceuticals unit cushioned a steep fall in sales of its medical devices due to the COVID-19 pandemic.

Johnson & Johnson raised its full-year profit forecast and beat analysts' estimates for quarterly earnings on Thursday as strength in its pharmaceuticals unit cushioned a steep fall in sales of its medical devices due to the COVID-19 pandemic.

The healthcare conglomerate, which is among the companies racing to develop a vaccine for the coronavirus, is planning to begin human studies later this month.

Meanwhile, Moderna Inc is gearing up to begin late-stage studies later this month, while AstraZeneca Plc is expected to report results from its experimental coronavirus vaccine soon.

Sales of medical devices at J&J tumbled by a third in the second quarter as hospitals and patients delayed non-urgent procedures like hip and knee replacements, but J.P. Morgan analyst Chris Schott said the unit seems to be benefiting from a faster-than-expected rebound in these procedures.

Some states have started to resume elective procedures, and J&J said in April that it expects a recovery in the fourth quarter of this year.

A strong performance by its pharmaceuticals business, its biggest, offset some of the slump in medical device sales. The unit was helped by strong demand for Stelara, used to treat Crohn's disease and plaque psoriasis, and cancer drug Darzalex.

The company raised its full-year adjusted profit forecast to $7.75 to $7.95 per share, from its prior estimate of $7.50 to $7.90 per share.

J&J reported net earnings of $3.63 billion, or $1.36 per share, in the second quarter, down from $5.61 billion, or $2.08 per share, a year earlier.

Excluding items, J&J earned $1.67 per share, beating the average analyst estimate of $1.49, according to Refinitiv estimate.

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.78% 8767 Delayed Quote.15.25%
MODERNA, INC. 5.24% 77.98 Delayed Quote.298.67%
share with twitter share with LinkedIn share with facebook
Latest news "Economy & Forex"
08/04Australian retailers suffer worst quarter in 2 decades, exports shine
RE
08/04S.Korea to convert golf courses, military sites into residential apartments to supply new homes
RE
08/04Facebook leases workspace at landmark New York building
RE
08/04U.S. FAA lays plan for Boeing 737 MAX's return; hurdles remain
RE
08/04With eye on China, India looks to increase barriers on imports from Asia
RE
08/04EXPLAINER : How the next WTO chief will be chosen and the task ahead
RE
08/04U.K. Sanctions Guidance Adds to Warnings for Maritime Sector
DJ
08/04NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/04NEWS HIGHLIGHTS : Top Global Markets News of the Day
DJ
08/04Tokyo July core CPI rises 0.4% year-on-year
RE
Latest news "Economy & Forex"